[Chronic recurrent subileus caused by Strongyloides stercoralis infection under immunosuppressive therapy].

C. Franzen,V. Diehl,G. Fätkenheuer

1996-09-27

Abstract:

What problem does this paper attempt to address?

mRNA delivery in cancer immunotherapy

Yichen Zhong,Shi Du,Yizhou Dong

DOI: https://doi.org/10.1016/j.apsb.2023.03.001

Abstract:Messenger RNA (mRNA) has drawn much attention in the medical field. Through various treatment approaches including protein replacement therapies, gene editing, and cell engineering, mRNA is becoming a potential therapeutic strategy for cancers. However, delivery of mRNA into targeted organs and cells can be challenging due to the unstable nature of its naked form and the low cellular uptake. Therefore, in addition to mRNA modification, efforts have been devoted to developing nanoparticles for mRNA delivery. In this review, we introduce four categories of nanoparticle platform systems: lipid, polymer, lipid-polymer hybrid, and protein/peptide-mediated nanoparticles, together with their roles in facilitating mRNA-based cancer immunotherapies. We also highlight promising treatment regimens and their clinical translation.
From structural design to delivery: mRNA therapeutics for cancer immunotherapy

Feng Zhou,Lujia Huang,Shiqin Li,Wenfang Yang,Fangmin Chen,Zhixiong Cai,Xiaolong Liu,Wujun Xu,Vesa-Pekka Lehto,Ulrich Lächelt,Rongqin Huang,Yang Shi,Twan Lammers,Wei Tao,Zhi Ping Xu,Ernst Wagner,Zhiai Xu,Haijun Yu

DOI: https://doi.org/10.1002/EXP.20210146

2023-11-17

Abstract:mRNA therapeutics have emerged as powerful tools for cancer immunotherapy in accordance with their superiority in expressing all sequence-known proteins in vivo. In particular, with a small dosage of delivered mRNA, antigen-presenting cells (APCs) can synthesize mutant neo-antigens and multi-antigens and present epitopes to T lymphocytes to elicit antitumor effects. In addition, expressing receptors like chimeric antigen receptor (CAR), T-cell receptor (TCR), CD134, and immune-modulating factors including cytokines, interferons, and antibodies in specific cells can enhance immunological response against tumors. With the maturation of in vitro transcription (IVT) technology, large-scale and pure mRNA encoding specific proteins can be synthesized quickly. However, the clinical translation of mRNA-based anticancer strategies is restricted by delivering mRNA into target organs or cells and the inadequate endosomal escape efficiency of mRNA. Recently, there have been some advances in mRNA-based cancer immunotherapy, which can be roughly classified as modifications of the mRNA structure and the development of delivery systems, especially the lipid nanoparticle platforms. In this review, the latest strategies for overcoming the limitations of mRNA-based cancer immunotherapies and the recent advances in delivering mRNA into specific organs and cells are summarized. Challenges and opportunities for clinical applications of mRNA-based cancer immunotherapy are also discussed.
Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy

Hong-Li Wang,Zhi-Gang Wang,Shu-Lin Liu

DOI: https://doi.org/10.3390/molecules27175607

IF: 4.6

2022-09-01

Molecules

Abstract:Messenger RNA (mRNA) is being developed by researchers as a novel drug for the treatment or prevention of many diseases. However, to enable mRNA to fully exploit its effects in vivo, researchers need to develop safer and more effective mRNA delivery systems that improve mRNA stability and enhance the ability of cells to take up and release mRNA. To date, lipid nanoparticles are promising nanodrug carriers for tumor therapy, which can significantly improve the immunotherapeutic effects of conventional drugs by modulating mRNA delivery, and have attracted widespread interest in the biomedical field. This review focuses on the delivery of mRNA by lipid nanoparticles for cancer treatment. We summarize some common tumor immunotherapy and mRNA delivery strategies, describe the clinical advantages of lipid nanoparticles for mRNA delivery, and provide an outlook on the current challenges and future developments of this technology.

chemistry, multidisciplinary,biochemistry & molecular biology
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy

Yan Zong,Yi Lin,Tuo Wei,Qiang Cheng

DOI: https://doi.org/10.1002/adma.202303261

IF: 29.4

2023-05-19

Advanced Materials

Abstract:Messenger RNA (mRNA) has received great attention in the prevention and treatment of various diseases due to the success of COVID‐19 mRNA vaccines (Comirnaty and Spikevax). To meet the therapeutic purpose, it is required that mRNA must enter the target cells and express sufficient proteins. Therefore, the development of effective delivery systems is necessary and crucial. Lipid nanoparticle (LNP) represents a remarkable vehicle that has indeed accelerated mRNA applications in humans, as several mRNA‐based therapies have already been approved or are in clinical trials. In this review, we focus on mRNA‐LNP mediated anticancer therapy. We summarize the main development strategies of mRNA‐LNP formulations, discuss representative therapeutic approaches in cancer, and point out current challenges and possible future directions of this research field. We hope these delivered messages could help further improve the application of mRNA‐LNP technology in cancer therapy. This article is protected by copyright. All rights reserved

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects

Tao Huang,Lushan Peng,Yingying Han,Dan Wang,Xiaoyun He,Junpu Wang,Chunlin Ou

DOI: https://doi.org/10.3389/fimmu.2022.922301

IF: 7.3

2022-08-26

Frontiers in Immunology

Abstract:Messenger RNA (mRNA) vaccines constitute an emerging therapeutic method with the advantages of high safety and efficiency as well as easy synthesis; thus, they have been widely used in various human diseases, especially in malignant cancers. However, the mRNA vaccine technology has some limitations, such as instability and low transitive efficiency in vivo , which greatly restrict its application. The development of nanotechnology in the biomedical field offers new strategies and prospects for the early diagnosis and treatment of human cancers. Recent studies have demonstrated that Lipid nanoparticle (LNP)-based mRNA vaccines can address the poor preservation and targeted inaccuracy of mRNA vaccines. As an emerging cancer therapy, mRNA vaccines potentially have broad future applications. Unlike other treatments, cancer mRNA vaccines provide specific, safe, and tolerable treatments. Preclinical studies have used personalized vaccines to demonstrate the anti-tumor effect of mRNA vaccines in the treatment of various solid tumors, including colorectal and lung cancer, using these in a new era of therapeutic cancer vaccines. In this review, we have summarized the latest applications and progress of LNP-based mRNA vaccines in cancers, and discussed the prospects and limitations of these fields, thereby providing novel strategies for the targeted therapy of cancers.

immunology
Path towards mRNA delivery for cancer immunotherapy from bench to bedside

Wenfei Chen,Yining Zhu,Jinhan He,Xun Sun

DOI: https://doi.org/10.7150/thno.89247

IF: 11.6

2024-01-01

Theranostics

Abstract:Messenger RNA (mRNA) has emerged as a promising therapeutic agent for the prevention and treatment of various diseases. mRNA vaccines, in particular, offer an alternative approach to conventional vaccines, boasting high potency, rapid development capabilities, cost-effectiveness, and safe administration. However, the clinical application of mRNA vaccines is hindered by the challenges of mRNA instability and inefficient in vivo delivery. In recent times, remarkable technological advancements have emerged to address these challenges, utilizing two main approaches: ex vivo transfection of dendritic cells (DCs) with mRNA and direct injection of mRNA-based therapeutics, either with or without a carrier. This review offers a comprehensive overview of major non-viral vectors employed for mRNA vaccine delivery. It showcases notable preclinical and clinical studies in the field of cancer immunotherapy and discusses important considerations for advancing these promising vaccine platforms for broader therapeutic applications. Additionally, we provide insights into future possibilities and the remaining challenges in mRNA delivery technology, emphasizing the significance of ongoing research in mRNA-based therapeutics.

medicine, research & experimental
Emerging advances in delivery systems for mRNA cancer vaccines

Zhimei Jiang,Yanhua Xu,Guangsheng Du,Xun Sun

DOI: https://doi.org/10.1016/j.jconrel.2024.04.039

Abstract:The success of lipid nanoparticles (LNPs) in treating COVID-19 promotes further research of mRNA vaccines for cancer vaccination. Aiming at overcoming the constraints of currently available mRNA carriers, various alternative nano-vectors have been developed for delivering tumor antigen encoding mRNA and showed versatility to induce potent anti-tumor immunity. The rationally designed nano-vaccines increase the immune activation capacity of the mRNA vaccines by promoting crucial aspects including mRNA stability, cellular uptake, endosomal escape and targeting of immune cells or organs. Herein, we summarized the research progress of various mRNA based nano-vaccines that have been reported for cancer vaccination, including LNPs, lipid enveloped hybrid nanoparticles, polymeric nanoparticles etc. Several strategies that have been reported for further enhancing the immune stimulation efficacy of mRNA nano-vaccines, including developing nano-vaccines for co-delivering adjuvants, combination of immune checkpoint inhibitors, and optimizing the injection routes for boosting immune responses, have been reviewed. The progress of mRNA nano-vaccines in clinical trials and the prospect of the mRNA vaccines for cancer vaccination are also discussed.
Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy

Li-Juan Duan,Qian Wang,Cuilian Zhang,Dong-Xiao Yang,Xu-Yao Zhang

DOI: https://doi.org/10.3389/fimmu.2022.923647

IF: 7.3

2022-05-26

Frontiers in Immunology

Abstract:Immunotherapy has become the breakthrough strategies for treatment of cancer in recent years. The application of messenger RNA in cancer immunotherapy is gaining tremendous popularity as mRNA can function as an effective vector for the delivery of therapeutic antibodies on immune targets. The high efficacy, decreased toxicity, rapid manufacturing and safe administration of mRNA vaccines have great advantages over conventional vaccines. The unprecedent success of mRNA vaccines against infection has proved its effectiveness. However, the instability and inefficient delivery of mRNA has cast a shadow on the wide application of this approach. In the past decades, modifications on mRNA structure and delivery methods have been made to solve these questions. This review summarizes recent advancements of mRNA vaccines in cancer immunotherapy and the existing challenges for its clinical application, providing insights on the future optimization of mRNA vaccines for the successful treatment of cancer.

immunology
Recent progress in mRNA cancer vaccines

Ruhui Yao,Chunyuan Xie,Xiaojun Xia

DOI: https://doi.org/10.1080/21645515.2024.2307187

2024-01-30

Human Vaccines & Immunotherapeutics

Abstract:The research and development of messenger RNA (mRNA) cancer vaccines have gradually overcome numerous challenges through the application of personalized cancer antigens, structural optimization of mRNA, and the development of alternative RNA-based vectors and efficient targeted delivery vectors. Clinical trials are currently underway for various cancer vaccines that encode tumor-associated antigens (TAAs), tumor-specific antigens (TSAs), or immunomodulators. In this paper, we summarize the optimization of mRNA and the emergence of RNA-based expression vectors in cancer vaccines. We begin by reviewing the advancement and utilization of state-of-the-art targeted lipid nanoparticles (LNPs), followed by presenting the primary classifications and clinical applications of mRNA cancer vaccines. Collectively, mRNA vaccines are emerging as a central focus in cancer immunotherapy, offering the potential to address multiple challenges in cancer treatment, either as standalone therapies or in combination with current cancer treatments.

immunology,biotechnology & applied microbiology
Direction of hair whorl and handedness

A. Beaton,G. Mellor

DOI: https://doi.org/10.1080/13576500601112358

2007-06-05

Abstract:We recorded the direction of hair whorl rotation in samples of male right- and non-right-handers. The data corroborate those of Klar (2003) in showing equal numbers of clockwise and anti-clockwise whorls in non-right-handers but an excess of clockwise whorls in right-handers. The findings support the view that in some proportion of the population direction of coiling arises as a consequence of random events occurring during early (pre-natal) development of the nervous system, while in the remainder of the population there is a systematic bias towards a clockwise direction of rotation. The association with handedness implies that the latter is in a very large measure biologically rather than culturally determined.
Heavy drinking in hospital patients.

K. Seppä,R. Mäkelä

DOI: https://doi.org/10.1111/J.1360-0443.1993.TB02024.X

1993-10-01

Addiction

Abstract:The study examines the prevalence of high consumption of alcohol among the patients of a large university hospital, and the ability of physicians to detect heavy drinking. According to self-report, the results of CAGE questionnaire or the physicians' opinion, 25% of the male and 11% of the female patients were heavy drinkers. The physicians identified 43% and 26% of the men and women who screened positively either according to CAGE or self-report. On the other hand, 17% of the men and 14% of the women who were identified by the physicians as heavy drinkers had a negative screening result. Heavy drinking was most often connected with psychiatric disorders, but it was present in all specialties. A wide range of diagnoses were found among abusers. It is concluded that all patients in all clinics should be asked about their drinking habits instead of relying solely on the physician's instinct or on the patient's self-report or CAGE. More individual interviews should be done to make possible early intervention in heavy drinking.
Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy

Maria L. Guevara,Francesca Persano,Stefano Persano

DOI: https://doi.org/10.3389/fchem.2020.589959

IF: 5.5

2020-10-23

Frontiers in Chemistry

Abstract:Over the past decade, messenger RNA (mRNA) has emerged as potent and flexible platform for the development of novel effective cancer immunotherapies. Advances in non-viral gene delivery technologies, especially the tremendous progress in lipid nanoparticles' manufacturing, have made possible the implementation of mRNA-based antitumor treatments. Several mRNA-based immunotherapies have demonstrated antitumor effect in preclinical and clinical studies, and marked successes have been achieved most notably by its implementation in therapeutic vaccines, cytokines therapies, checkpoint blockade and chimeric antigen receptor (CAR) cell therapy. In this review, we summarize recent advances in the development of lipid nanoparticles for mRNA-based immunotherapies and their applications in cancer treatment. Finally, we also highlight the variety of immunotherapeutic approaches through mRNA delivery and discuss the main factors affecting transfection efficiency and tropism of mRNA-loaded lipid nanoparticles in vivo.

chemistry, multidisciplinary
mRNA vaccine for cancer immunotherapy

Lei Miao,Yu Zhang,Leaf Huang

DOI: https://doi.org/10.1186/s12943-021-01335-5

IF: 37.3

2021-02-25

Molecular Cancer

Abstract:Abstract mRNA vaccines have become a promising platform for cancer immunotherapy. During vaccination, naked or vehicle loaded mRNA vaccines efficiently express tumor antigens in antigen-presenting cells (APCs), facilitate APC activation and innate/adaptive immune stimulation. mRNA cancer vaccine precedes other conventional vaccine platforms due to high potency, safe administration, rapid development potentials, and cost-effective manufacturing. However, mRNA vaccine applications have been limited by instability, innate immunogenicity, and inefficient in vivo delivery. Appropriate mRNA structure modifications (i.e., codon optimizations, nucleotide modifications, self-amplifying mRNAs, etc.) and formulation methods (i.e., lipid nanoparticles (LNPs), polymers, peptides, etc.) have been investigated to overcome these issues. Tuning the administration routes and co-delivery of multiple mRNA vaccines with other immunotherapeutic agents (e.g., checkpoint inhibitors) have further boosted the host anti-tumor immunity and increased the likelihood of tumor cell eradication. With the recent U.S. Food and Drug Administration (FDA) approvals of LNP-loaded mRNA vaccines for the prevention of COVID-19 and the promising therapeutic outcomes of mRNA cancer vaccines achieved in several clinical trials against multiple aggressive solid tumors, we envision the rapid advancing of mRNA vaccines for cancer immunotherapy in the near future. This review provides a detailed overview of the recent progress and existing challenges of mRNA cancer vaccines and future considerations of applying mRNA vaccine for cancer immunotherapies.

oncology,biochemistry & molecular biology
Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity

Liusheng Wu,Xiaoqiang Li,Xinye Qian,Shuang Wang,Jixian Liu,Jun Yan

DOI: https://doi.org/10.3390/vaccines12020186

2024-02-13

Vaccines

Abstract:In recent years, lipid nanoparticles (LNPs) have attracted extensive attention in tumor immunotherapy. Targeting immune cells in cancer therapy has become a strategy of great research interest. mRNA vaccines are a potential choice for tumor immunotherapy, due to their ability to directly encode antigen proteins and stimulate a strong immune response. However, the mode of delivery and lack of stability of mRNA are key issues limiting its application. LNPs are an excellent mRNA delivery carrier, and their structural stability and biocompatibility make them an effective means for delivering mRNA to specific targets. This study summarizes the research progress in LNP delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity. The role of LNPs in improving mRNA stability, immunogenicity, and targeting is discussed. This review aims to systematically summarize the latest research progress in LNP delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity to provide new ideas and strategies for tumor immunotherapy, as well as to provide more effective treatment plans for patients.

immunology,medicine, research & experimental
Targeting and Therapeutic Aspects

Yaping Liu,Yingying Huang,Guantao He,Chun Guo,Jinhua Dong,Linping Wu

DOI: https://doi.org/10.3390/ijms251810166

IF: 5.6

2024-09-23

International Journal of Molecular Sciences

Abstract:Lipid nanoparticles (LNPs) have emerged as leading non-viral carriers for messenger RNA (mRNA) delivery in clinical applications. Overcoming challenges in safe and effective mRNA delivery to target tissues and cells, along with controlling release from the delivery vehicle, remains pivotal in mRNA-based therapies. This review elucidates the structure of LNPs, the mechanism for mRNA delivery, and the targeted delivery of LNPs to various cells and tissues, including leukocytes, T-cells, dendritic cells, Kupffer cells, hepatic endothelial cells, and hepatic and extrahepatic tissues. Here, we discuss the applications of mRNA–LNP vaccines for the prevention of infectious diseases and for the treatment of cancer and various genetic diseases. Although challenges remain in terms of delivery efficiency, specific tissue targeting, toxicity, and storage stability, mRNA–LNP technology holds extensive potential for the treatment of diseases.

biochemistry & molecular biology,chemistry, multidisciplinary
Delivery approaches of immunomodulatory nucleic acids for cancer therapy

Xiaomeng Hu,Tom Enbar,Li Tang

DOI: https://doi.org/10.1016/j.copbio.2024.103182

Abstract:Messenger RNA (mRNA) vaccines have made remarkable public health contributions during the pandemic and initiated a new era for nucleic acid-based therapeutics. With the unique strength of nucleic acids, including not only mRNA but also DNA, microRNA, small interfering RNA (siRNA), and other nucleic acids, either in tuning off genes or introducing function, nucleic acid therapeutics have been regarded as potential candidates for the treatment of many different diseases, especially for the immunomodulation in cancer. However, the scope of the applications was limited by the challenges in delivery due to intrinsic properties of nucleic acids including low stability, immunogenicity, and toxicity. Bioengineering approaches toward efficient and targeted delivery of therapeutic nucleic acids have gained momentum in clinical applications in the past few decades. Recent advances in the biotechnological approaches for the delivery of mRNA, siRNA, and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas for immunomodulatory are promising alternatives in designing future cancer immunotherapy.
RNA Cancer Nanomedicine: Nanotechnology-Mediated RNA Therapy.

Bijan Emiliano Ferdows,Dylan Neal Patel,Wei Chen,Xiangang Huang,Na Kong,Wei Tao

DOI: https://doi.org/10.1039/d1nr06991h

IF: 6.7

2022-01-01

Nanoscale

Abstract:It has been demonstrated that RNA molecules-mRNA, siRNA, microRNA, and sgRNA-regulate cancer-specific genes, and therefore, RNA-based therapeutics can suppress tumor progression and metastasis by selectively upregulating and silencing these genes. However, the innate defense mechanisms (e.g., exonucleases and RNases) involving the human immune system catalyze the degradation of exogenous RNAs. Thus, nonviral nanoparticles have been employed to deliver therapeutic RNAs for effective cancer gene therapy. In this minireview, we highlight efforts in the past decade to deliver therapeutic RNAs for cancer therapy using novel nanoparticles. Specifically, we review nanoparticles, including lipid, polymer, inorganic, and biomimetic materials, which have been employed to deliver therapeutic RNAs and evoke tumor suppressing responses. Finally, we discuss the challenges and considerations that may accelerate the clinical translation of nanotechnology-mediated RNA therapy.
mRNA-based cancer therapeutics

Chuang Liu,Qiangqiang Shi,Xiangang Huang,Seyoung Koo,Na Kong,Wei Tao

DOI: https://doi.org/10.1038/s41568-023-00586-2

IF: 78.5

2023-06-14

Nature Reviews Cancer

Abstract:Due to the fact that mRNA technology allows the production of diverse vaccines and treatments in a shorter time frame and with reduced expense compared to conventional approaches, there has been a surge in the use of mRNA-based therapeutics in recent years. With the aim of encoding tumour antigens for cancer vaccines, cytokines for immunotherapy, tumour suppressors to inhibit tumour development, chimeric antigen receptors for engineered T cell therapy or genome-editing proteins for gene therapy, many of these therapeutics have shown promising efficacy in preclinical studies, and some have even entered clinical trials. Given the evidence supporting the effectiveness and safety of clinically approved mRNA vaccines, coupled with growing interest in mRNA-based therapeutics, mRNA technology is poised to become one of the major pillars in cancer drug development. In this Review, we present in vitro transcribed mRNA-based therapeutics for cancer treatment, including the characteristics of the various types of synthetic mRNA, the packaging systems for efficient mRNA delivery, preclinical and clinical studies, current challenges and future prospects in the field. We anticipate the translation of promising mRNA-based treatments into clinical applications, to ultimately benefit patients.

oncology
Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood.

M. Lein,L. Nowak,K. Jung,F. Koenig,R. Lichtinghagen,D. Schnorr,S. Loening

DOI: https://doi.org/10.1016/S0009-9120(97)00097-0

IF: 3.625

1997-08-01

Clinical Biochemistry

Abstract:
mRNA: A promising platform for cancer immunotherapy

Byoungjae Kong,Yelee Kim,Eun Hye Kim,Jung Soo Suk,Yoosoo Yang

DOI: https://doi.org/10.1016/j.addr.2023.114993

Abstract:Messenger RNA (mRNA) is now in the limelight as a powerful tool for treating various human diseases, especially malignant tumors, thanks to the remarkable clinical outcomes of mRNA vaccines using lipid nanoparticle technology during the COVID-19 pandemic. Recent promising preclinical and clinical results that epitomize the advancement in mRNA and nanoformulation-based delivery technologies have highlighted the tremendous potential of mRNA in cancer immunotherapy. mRNAs can be harnessed for cancer immunotherapy in forms of various therapeutic modalities, including cancer vaccines, adoptive T-cell therapies, therapeutic antibodies, and immunomodulatory proteins. This review provides a comprehensive overview of the current state and prospects of mRNA-based therapeutics, including numerous delivery and therapeutic strategies.

[Chronic recurrent subileus caused by Strongyloides stercoralis infection under immunosuppressive therapy].

mRNA delivery in cancer immunotherapy

From structural design to delivery: mRNA therapeutics for cancer immunotherapy

Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy

Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy

Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects

Path towards mRNA delivery for cancer immunotherapy from bench to bedside

Emerging advances in delivery systems for mRNA cancer vaccines

Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy

Recent progress in mRNA cancer vaccines

Direction of hair whorl and handedness

Heavy drinking in hospital patients.

Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy

mRNA vaccine for cancer immunotherapy

Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity

Targeting and Therapeutic Aspects

Delivery approaches of immunomodulatory nucleic acids for cancer therapy

RNA Cancer Nanomedicine: Nanotechnology-Mediated RNA Therapy.

mRNA-based cancer therapeutics

Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood.

mRNA: A promising platform for cancer immunotherapy